Low-Dose Acyclovir Reduces the Reactivation of Herpes Simplex and Varicella Zoster Viruses After Allogeneic Stem Cell Transplantation
Oral acyclovir 400 mg taken twice daily for prophylaxis in alloSCT recipients is both effective and well-tolerated. This lower-dose regimen effectively prevents HSV and VZV reactivation without compromising efficacy or patient safety.
Authors
- Gina Patrus
- Sorana G Ursu (ORCID: https://orcid.org/0000-0002-0496-5788)
- Salman Fazal
- Mohammad M. Alhousani
Institutions
- Allegheny Health Network (US)
Publication Details
- Journal
- Cureus
- Published
- 2024-12-07
- DOI
- https://doi.org/10.7759/cureus.75270
- Primary Topic
- Herpesvirus Infections and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00